Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
B 4.08 0.99% 0.04
OMER closed up 0.99 percent on Friday, November 1, 2024, on 81 percent of normal volume.
Earnings due: Nov 7
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Inside Day Range Contraction 0.00%
Fell Below 20 DMA Bearish 0.99%
Overbought Stochastic Strength -3.32%
Pocket Pivot Bullish Swing Setup -4.90%
NR7 Range Contraction -4.90%
Overbought Stochastic Strength -4.90%
Pocket Pivot Bullish Swing Setup -4.23%
Stochastic Reached Overbought Strength -4.23%
Upper Bollinger Band Walk Strength -4.23%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 17 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
20 DMA Resistance about 18 hours ago
Up 3% about 19 hours ago
60 Minute Opening Range Breakout about 21 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Omeros Corporation Description

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Surgery Inflammation Disorders Clinical Research Ophthalmology Clinical Trial Urology Schizophrenia Macular Degeneration Cataracts Perfusion Wet Age Related Macular Degeneration Hemoglobin Surgical Specialties Movement Disorders Cognitive Disorders Ischemia Addiction Intraocular Lens Arthroscopy Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Hemolytic Uremic Syndrome

Is OMER a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.68
52 Week Low 1.13
Average Volume 219,003
200-Day Moving Average 3.93
50-Day Moving Average 3.98
20-Day Moving Average 4.08
10-Day Moving Average 4.18
Average True Range 0.18
RSI (14) 50.00
ADX 30.76
+DI 17.25
-DI 13.14
Chandelier Exit (Long, 3 ATRs) 3.82
Chandelier Exit (Short, 3 ATRs) 4.29
Upper Bollinger Bands 4.38
Lower Bollinger Band 3.78
Percent B (%b) 0.5
BandWidth 14.52
MACD Line 0.05
MACD Signal Line 0.06
MACD Histogram -0.0033
Fundamentals Value
Market Cap 256.49 Million
Num Shares 62.9 Million
EPS -2.89
Price-to-Earnings (P/E) Ratio -1.41
Price-to-Sales 4.93
Price-to-Book 8.44
PEG Ratio -0.17
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.28
Resistance 3 (R3) 4.28 4.23 4.24
Resistance 2 (R2) 4.23 4.18 4.22 4.23
Resistance 1 (R1) 4.15 4.15 4.15 4.15 4.22
Pivot Point 4.10 4.10 4.09 4.09 4.10
Support 1 (S1) 4.02 4.05 4.02 4.02 3.94
Support 2 (S2) 3.97 4.02 3.96 3.93
Support 3 (S3) 3.89 3.97 3.92
Support 4 (S4) 3.89